{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T22:23:05Z","timestamp":1780525385079,"version":"3.54.1"},"reference-count":245,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,9,26]],"date-time":"2020-09-26T00:00:00Z","timestamp":1601078400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100013994","name":"Sociedade Brasileira de Dermatologia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013994","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Anais Brasileiros de Dermatologia"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.abd.2020.09.001","type":"journal-article","created":{"date-parts":[[2020,10,2]],"date-time":"2020-10-02T23:44:22Z","timestamp":1601682262000},"page":"19-38","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":61,"special_numbering":"S1","title":["Consensus on the use of oral isotretinoin in dermatology - Brazilian Society of Dermatology"],"prefix":"10.1016","volume":"95","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7190-8241","authenticated-orcid":false,"given":"Edil\u00e9ia","family":"Bagatin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2117-6537","authenticated-orcid":false,"given":"Caroline Sousa","family":"Costa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1090-177X","authenticated-orcid":false,"given":"Marco Alexandre Dias da","family":"Rocha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7375-9232","authenticated-orcid":false,"given":"Fab\u00edola Rosa","family":"Picosse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6548-7452","authenticated-orcid":false,"given":"Cristhine Souza Le\u00e3o","family":"Kamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5644-4351","authenticated-orcid":false,"given":"Rodrigo","family":"Pirmez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3604-3128","authenticated-orcid":false,"given":"Mayra","family":"Ianhez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2596-9294","authenticated-orcid":false,"given":"H\u00e9lio Amante","family":"Miot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.abd.2020.09.001_bib0005","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1111\/j.1365-2133.1982.tb00410.x","article-title":"A double-blind study of the effects of 13-cis-retinoic acid on acne, sebum excretion rate and microbial population","volume":"107","author":"King","year":"1982","journal-title":"Br J Dermatol"},{"issue":"Pt 2 Suppl","key":"10.1016\/j.abd.2020.09.001_bib0010","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0190-9622(82)70063-5","article-title":"Isotretinoin versus placebo in the treatment of cystic acne. A randomized double-blind study","volume":"6","author":"Peck","year":"1982","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.abd.2020.09.001_bib0015","unstructured":"European Medicines Agency. Roaccutane was registered in all EU Member States, except Sweden, from 1983. [cited 04.13.20] Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/referrals\/roaccutane."},{"key":"10.1016\/j.abd.2020.09.001_bib0020","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1590\/S0365-05962008000400012","article-title":"A 65-year experience treating acne, including 26 years with oral isotretinoin","volume":"83","author":"Sampaio","year":"2008","journal-title":"An Bras Dermatol"},{"key":"10.1016\/j.abd.2020.09.001_bib0025","doi-asserted-by":"crossref","first-page":"162","DOI":"10.4161\/derm.1.3.9364","article-title":"The use of isotretinoin in acne","volume":"1","author":"Layton","year":"2009","journal-title":"Dermatoendocrinol"},{"key":"10.1016\/j.abd.2020.09.001_bib0030","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1001\/archderm.143.9.1187","article-title":"What is the chance of a normal pregnancy in a woman whose fetus has been exposed to isotretinoin?","volume":"143","author":"Sladden","year":"2007","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.abd.2020.09.001_bib0035","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1001\/jamadermatol.2019.1388","article-title":"US Food and Drug Administration reports of pregnancy and pregnancy-related adverse events associated with isotretinoin","volume":"155","author":"Tkachenko","year":"2019","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.abd.2020.09.001_bib0040","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1586\/edm.10.58","article-title":"Oral isotretinoin: the most promising dermatological off-label uses","volume":"5","author":"Bagatin","year":"2010","journal-title":"Exp Rev Dermatol"},{"key":"10.1016\/j.abd.2020.09.001_bib0045","first-page":"231","article-title":"Topical trifarotene: a new retinoid","volume":"179","author":"Balak","year":"2018","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.abd.2020.09.001_bib0050","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1046\/j.1439-0353.2004.03739.x","article-title":"Low dose isotretinoin combined with tretinoin is effective to correct abnormalities of acne","volume":"2","author":"Plewig","year":"2004","journal-title":"J Dtsch Dermatol Ges"},{"key":"10.1016\/j.abd.2020.09.001_bib0055","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1038\/jid.2008.338","article-title":"Isotretinoin temporally regulates distinct sets of genes in patient skin","volume":"129","author":"Nelson","year":"2009","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.abd.2020.09.001_bib0060","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1111\/j.1365-2133.2012.10949.x","article-title":"Immunoregulatory effects of isotretinoin in patients with acne","volume":"167","author":"Karadag","year":"2012","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.abd.2020.09.001_bib0065","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1111\/j.1365-2133.2011.10392.x","article-title":"TRAIL contributes to the apoptotic effect of 13-cis retinoic acid in human sebaceous gland cells","volume":"165","author":"Nelson","year":"2011","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.abd.2020.09.001_bib0070","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1186\/s12967-017-1297-2","article-title":"p53: key conductor of all anti-acne therapies","volume":"15","author":"Melnik","year":"2017","journal-title":"J Transl Med"},{"key":"10.1016\/j.abd.2020.09.001_bib0075","doi-asserted-by":"crossref","first-page":"173","DOI":"10.2340\/00015555-2535","article-title":"Apoptosis may explain the pharmacological mode of action and adverse effects of isotretinoin, including teratogenicity","volume":"97","author":"Melnik","year":"2017","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.abd.2020.09.001_bib0080","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1111\/bjd.14564","article-title":"Acne vulgaris: an inflammasomopathy of the sebaceous follicle induced by deviated FoxO1\/mTORC1 signalling","volume":"174","author":"Melnik","year":"2016","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.abd.2020.09.001_bib0085","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/jid.2010.281","article-title":"Propionibacterium acnes activates the IGF-1\/IGF-1R system in the epidermis and induces keratinocyte proliferation","volume":"131","author":"Isard","year":"2011","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.abd.2020.09.001_bib0090","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1038\/sj.jid.5700289","article-title":"13-cis Retinoic acid induces apoptosis and cell cycle arrest in human SEB-1 sebocytes","volume":"126","author":"Nelson","year":"2006","journal-title":"J Invest Dermatol"},{"issue":"Suppl 1","key":"10.1016\/j.abd.2020.09.001_bib0095","first-page":"S47","article-title":"Isotretinoin: state of the art treatment for acne vulgaris","volume":"8","author":"Ganceviciene","year":"2010","journal-title":"J Dtsch Dermatol Ges"},{"key":"10.1016\/j.abd.2020.09.001_bib0100","doi-asserted-by":"crossref","first-page":"2198","DOI":"10.1038\/jid.2012.111","article-title":"Systemic isotretinoin therapy normalizes exaggerated TLR-2-mediated innate immune responses in acne patients","volume":"132","author":"Dispenza","year":"2012","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.abd.2020.09.001_bib0105","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1097\/ICO.0000000000002229","article-title":"Effects of different doses of systemic isotretinoin on eyes: a histopathological and immunohistochemical study in rats","volume":"39","author":"Karadag","year":"2020","journal-title":"Cornea"},{"key":"10.1016\/j.abd.2020.09.001_bib0110","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1055\/s-2007-961813","article-title":"All-trans-retinoic acid and 13-cis-retinoic acid: pharmacokinetics and biological activity in different cell culture models of human keratinocytes","volume":"39","author":"Schroeder","year":"2007","journal-title":"Horm Metab Res"},{"key":"10.1016\/j.abd.2020.09.001_bib0115","first-page":"22","article-title":"Updated physician's guide to the off-label uses of oral isotretinoin","volume":"7","author":"Nickle","year":"2014","journal-title":"J Clin Aesthet Dermatol"},{"key":"10.1016\/j.abd.2020.09.001_bib0120","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1080\/09546634.2017.1309349","article-title":"Retinoids: a journey from the molecular structures and mechanisms of action to clinical uses in dermatology and adverse effects","volume":"28","author":"Khalil","year":"2017","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.abd.2020.09.001_bib0125","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1080\/09546634.2018.1445194","article-title":"Dermatological indications for the use of isotretinoin beyond acne","volume":"29","author":"Forbat","year":"2018","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.abd.2020.09.001_bib0130","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1038\/jid.2013.446","article-title":"The global burden of skin disease in 2010: an analysis of the prevalence and impact of skin conditions","volume":"134","author":"Hay","year":"2014","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.abd.2020.09.001_bib0135","first-page":"383","article-title":"Global skin disease morbidity and mortality: an update from the global burden of disease study 2013","volume":"3","author":"Karimkhani","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.abd.2020.09.001_bib0140","first-page":"2136","article-title":"Prevalence, severity, and severity risk factors of acne in high school pupils: a community-based study","volume":"129","author":"Ghodsi","year":"2009","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.abd.2020.09.001_bib0145","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1111\/j.1365-2133.2007.08087.x","article-title":"Community-based study of acne vulgaris in adolescents in Singapore","volume":"57","author":"Tan","year":"2007","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.abd.2020.09.001_bib0150","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1590\/abd1806-4841.20142100","article-title":"Acne vulgaris: prevalence and clinical forms in adolescents from S\u00e3o Paulo, Brasil","volume":"89","author":"Bagatin","year":"2014","journal-title":"An Bras Dermatol"},{"key":"10.1016\/j.abd.2020.09.001_bib0155","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1111\/j.1365-2133.2011.10436.x","article-title":"Prevalence of skin lesions and need for treatment in a cohort of 90,880 workers","volume":"165","author":"Augustin","year":"2011","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.abd.2020.09.001_bib0160","doi-asserted-by":"crossref","first-page":"40","DOI":"10.2340\/00015555-1164","article-title":"Prevalence of acne vulgaris in Chinese adolescents and adults: a community-based study of 17,345 subjects in six cities","volume":"92","author":"Shen","year":"2012","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.abd.2020.09.001_bib0165","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1590\/abd1806-4841.20188802","article-title":"Profile of dermatological consultations in Brazil (2018)","volume":"93","author":"Sociedade Brasileira de Dermatologia","year":"2018","journal-title":"An Bras Dermatol"},{"key":"10.1016\/j.abd.2020.09.001_bib0170","first-page":"31","article-title":"Epidemiological spectrum of common dermatological conditions of patients attending dermatological consultations in Al-Majmaah Region (Kingdom of Saudi Arabia)","volume":"8","author":"Al-Hoqail","year":"2013","journal-title":"J Taibah Univ Med Sci"},{"key":"10.1016\/j.abd.2020.09.001_bib0175","first-page":"285","article-title":"Most common dermatologic conditions encountered by dermatologists and nondermatologists","volume":"94","author":"Wilmer","year":"2014","journal-title":"Cutis"},{"key":"10.1016\/j.abd.2020.09.001_bib0180","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.jaad.2015.12.037","article-title":"Guidelines of care for the management of acne vulgaris","volume":"74","author":"Zaenglein","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.abd.2020.09.001_bib0185","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1111\/j.1365-2133.2010.10060.x","article-title":"A prospective trial of the effects of isotretinoin on quality of life and depressive symptoms","volume":"163","author":"McGrath","year":"2010","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.abd.2020.09.001_bib0190","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1111\/jdv.12170","article-title":"Isotretinoin 5mg daily for low-grade adult acne vulgaris \u2013 a placebo-controlled, randomized double-blind study","volume":"28","author":"Rademaker","year":"2014","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.abd.2020.09.001_bib0195","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1111\/jdv.15048","article-title":"Which acne treatment has the best influence on health-related quality of life? Literature review by the European Academy of Dermatology and Venereology Task Force on Quality of Life and Patient Oriented Outcomes","volume":"32","author":"Chernyshov","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.abd.2020.09.001_bib0200","first-page":"CD009435","article-title":"Oral isotretinoin for acne","volume":"11","author":"Costa","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.abd.2020.09.001_bib0205","series-title":"Aprova o Protocolo de uso da isotretino\u00edna no tratamento da acne grave","author":"Brasil. Minist\u00e9rio da Sa\u00fade, Secretaria de Aten\u00e7\u00e3o \u00e0 Sa\u00fade. Portaria N\u00b0. 1159","year":"2015"},{"issue":"Suppl 1","key":"10.1016\/j.abd.2020.09.001_bib0210","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.jaad.2017.09.078","article-title":"Practical management of acne for clinicians: an international consensus from the Global Alliance to Improve Outcomes in Acne","volume":"78","author":"Thiboutot","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.abd.2020.09.001_bib0215","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/S0190-9622(80)80074-0","article-title":"The treatment of severe cystic acne with 13-cis-retinoic acid. Evaluation of sebum production and the clinical response in a multiple-dose trial","volume":"3","author":"Farrell","year":"1980","journal-title":"J Am Acad Dermatol"},{"issue":"Pt 2","key":"10.1016\/j.abd.2020.09.001_bib0220","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/S0190-9622(82)70066-0","article-title":"Comparative effect of isotretinoin and etretinate on acne and sebaceous gland secretion","volume":"6 Suppl 4","author":"Goldstein","year":"1982","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.abd.2020.09.001_bib0225","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1111\/j.1365-2133.1983.tb03973.x","article-title":"A dose\u2013response study of I3-cis-retinoic acid in acne vulgaris","volume":"108","author":"Jones","year":"1983","journal-title":"Br J Dermatol"},{"issue":"Suppl 24","key":"10.1016\/j.abd.2020.09.001_bib0230","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1365-2133.1983.tb11574.x","article-title":"A comparison of 13-cis-retinoic acid and erythromycin treatment in severe acne","volume":"109","author":"Jones","year":"1983","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.abd.2020.09.001_bib0235","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1159\/000249803","article-title":"Dose\u2013response relationship in isotretinoin therapy for conglobate acne","volume":"167","author":"Van der Meeren","year":"1983","journal-title":"Dermatologica"},{"key":"10.1016\/j.abd.2020.09.001_bib0240","first-page":"623","article-title":"13-cis-retinoic acid. Low dosage oral use in acne papulopustulosa. Results of a multicenter study","volume":"35","author":"Corlin","year":"1984","journal-title":"Hautarzt"},{"key":"10.1016\/j.abd.2020.09.001_bib0245","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/S0190-9622(84)80100-0","article-title":"Isotretinoin therapy for acne: results of a multicenter dose-response study","volume":"10","author":"Strauss","year":"1984","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.abd.2020.09.001_bib0250","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1159\/000249321","article-title":"Isotretinoin versus minocycline in cystic acne: a study of lipid metabolism","volume":"172","author":"Pigatto","year":"1986","journal-title":"Dermatologica"},{"key":"10.1016\/j.abd.2020.09.001_bib0255","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1111\/j.1365-4362.1985.tb05775.x","article-title":"Isotretinoin and tetracycline in the management of severe nodulocystic acne","volume":"24","author":"Lester","year":"1985","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.abd.2020.09.001_bib0260","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/j.1365-2230.1988.tb00659.x","article-title":"A comparison of dapsone with 13-cis retinoic acid in the treatment of nodular cystic acne","volume":"13","author":"Prendiville","year":"1988","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.abd.2020.09.001_bib0265","first-page":"538","article-title":"Comparison of combined azelaic acid cream plus oral minocycline with oral isotretinoin in severe acne","volume":"11","author":"Gollnick","year":"2001","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.abd.2020.09.001_bib0270","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1067\/mjd.2001.115965","article-title":"A randomized trial of the efficacy of a new micronized formulation versus a standard formulation of isotretinoin in patients with severe recalcitrant nodular acne","volume":"45","author":"Strauss","year":"2001","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.abd.2020.09.001_bib0275","first-page":"238","article-title":"Comparative efficacy and safety and efficacy of systemic 13-cis retinoic acid 20mg\/day vs. 40mg\/day in acne vulgaris","volume":"15","author":"Kapadia","year":"2005","journal-title":"J Pak Assoc Dermatol"},{"key":"10.1016\/j.abd.2020.09.001_bib0280","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s00403-007-0777-2","article-title":"Treatment of acne with intermittent and conventional isotretinoin: a randomized, controlled multicenter study","volume":"299","author":"Akman","year":"2007","journal-title":"Arch Dermatol Res"},{"key":"10.1016\/j.abd.2020.09.001_bib0285","doi-asserted-by":"crossref","first-page":"246","DOI":"10.2340\/00015555-0211","article-title":"Clinical and microbiological comparisons of isotretinoin vs. tetracycline in acne vulgaris","volume":"87","author":"Oprica","year":"2007","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.abd.2020.09.001_bib0290","doi-asserted-by":"crossref","first-page":"187","DOI":"10.4103\/0378-6323.39727","article-title":"Oral isotretinoin is as effective as a combination of oral isotretinoin and topical anti-acne agents in nodulocystic acne","volume":"74","author":"Dhir","year":"2008","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"10.1016\/j.abd.2020.09.001_bib0295","first-page":"9","article-title":"Isotretinoin versus weekly pulse dose azithromycin in the treatment of acne\u2014a comparative study","volume":"18","author":"Wahab","year":"2008","journal-title":"J Pak Assoc Dermatol"},{"key":"10.1016\/j.abd.2020.09.001_bib0300","doi-asserted-by":"crossref","first-page":"688","DOI":"10.4103\/0378-6323.86482","article-title":"Oral isotretinoin in different dose regimens for acne vulgaris: a randomized comparative trial","volume":"77","author":"Agarwal","year":"2011","journal-title":"Indian J Dermatol Venereol Leprol"},{"issue":"Suppl 1","key":"10.1016\/j.abd.2020.09.001_bib0305","first-page":"41","article-title":"Standard-dose isotretinoin vs. a combination of low-dose isotretinoin and azithromycin pulse in management of severe acne: preliminary report of a randomized study","volume":"165","author":"De","year":"2011","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.abd.2020.09.001_bib0310","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1111\/j.1365-2133.2010.10152.x","article-title":"Effectiveness of conventional, low-dose and intermittent oral isotretinoin in the treatment of acne: a randomized, controlled comparative study","volume":"164","author":"Lee","year":"2011","journal-title":"Br J Dermatol"},{"issue":"Suppl 1","key":"10.1016\/j.abd.2020.09.001_bib0315","first-page":"98","article-title":"Treatment of mild to moderate acne with three different modalities","volume":"165","author":"Leheta","year":"2011","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.abd.2020.09.001_bib0320","doi-asserted-by":"crossref","first-page":"177","DOI":"10.4103\/2277-9175.139413","article-title":"The efficacy of 5% dapsone gel plus oral isotretinoin versus oral isotretinoin alone in acne vulgaris: a randomized double-blind study","volume":"3","author":"Faghihi","year":"2014","journal-title":"Adv Biomed Res"},{"key":"10.1016\/j.abd.2020.09.001_bib0325","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1111\/bjd.13191","article-title":"A treatment for severe nodular acne: a randomized investigator-blinded, controlled, noninferiority trial comparing fixed-dose adapalene\/benzolyl peroxide plus doxycycline vs. oral isotretinoin","volume":"171","author":"Tan","year":"2014","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.abd.2020.09.001_bib0330","first-page":"665","article-title":"Results of a phase III, double-blind, randomized, parallel-group, non-inferiority study evaluating the safety and efficacy of isotretinoin-Lidose in patients with severe recalcitrant nodular acne","volume":"13","author":"Webster","year":"2014","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.abd.2020.09.001_bib0335","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1111\/dth.12213","article-title":"Analysis of clinical efficacy, side effects, and laboratory changes among patients with acne vulgaris receiving single versus twice daily dose of oral isotretinoin","volume":"28","author":"Ahmad","year":"2015","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.abd.2020.09.001_bib0340","doi-asserted-by":"crossref","first-page":"378","DOI":"10.4103\/2229-5178.190505","article-title":"A randomized comparative trial of two low-dose oral isotretinoin regimens in moderate to severe acne vulgaris","volume":"7","author":"Dhaked","year":"2016","journal-title":"Indian Dermatol Online J"},{"key":"10.1016\/j.abd.2020.09.001_bib0345","first-page":"941","article-title":"A randomized, open-label, comparative study of efficacy of low-dose continuous versus low-dose intermittent oral isotretinoin therapy in moderate-to-severe acne vulgaris","volume":"7","author":"Shetti","year":"2017","journal-title":"Natl J Physiol Pharm Pharmacol"},{"key":"10.1016\/j.abd.2020.09.001_bib0350","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/bjd.15668","article-title":"Efficacy and adverse events of oral isotretinoin for acne: a systematic review","volume":"178","author":"Vallerand","year":"2018","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.abd.2020.09.001_bib0355","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1111\/jdv.13776","article-title":"European evidence-based (S3) guideline for the treatment of acne \u2013 update 2016 \u2013 short version","volume":"30","author":"Nast","year":"2016","journal-title":"J EurAcad Dermatol Venereol"},{"key":"10.1016\/j.abd.2020.09.001_bib0360","unstructured":"American Academy of Dermatology. Position statement on isotretinoin (Approved by the Board of Directors December 9, 2000; amended by the Board of Directors March 25, 2003, March 11, 2004, November 13, 2010 and February 19, 2018). Available from: https:\/\/server.aad.org\/Forms\/Policies\/Uploads\/PS\/PS-Isotretinoin.pdf [accessed 20.10.19]."},{"key":"10.1016\/j.abd.2020.09.001_bib0365","unstructured":"British Association of Dermatologists. Patient Information Leaflets (PILs). Isotretinoin. Available from: http:\/\/www.bad.org.uk\/for-the-public\/patient-information-leaflets\/isotretinoin\/?showmore=1&returnlink=http%3A%2F%2Fwww.bad.org.uk%2Ffor-the-public%2Fpatient-information-leaflets-.Xa4RuC3OqCQ [accessed 20.10.19]."},{"key":"10.1016\/j.abd.2020.09.001_bib0370","unstructured":"The Australasian College of Dermatologists. The Australasian College of Dermatologists. Position Statement Isotretinoin for treatmentof acne. Available from: https:\/\/www.dermcoll.edu.au\/wp-content\/uploads\/ACD-Position-Statement-isotretinoin-June-2018.pdf [accessed 20.10.19]."},{"key":"10.1016\/j.abd.2020.09.001_bib0375","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1159\/000018130","article-title":"Predictive factors for failure of isotretinoin treatment in acne patients: results from a cohort of 237 patients","volume":"198","author":"Lehucher-Ceyrac","year":"1999","journal-title":"Dermatology"},{"key":"10.1016\/j.abd.2020.09.001_bib0380","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1159\/000090658","article-title":"Prospective study of risk factors of relapse after treatment of acne with oral isotretinoin","volume":"212","author":"Quereux","year":"2006","journal-title":"Dermatology"},{"key":"10.1016\/j.abd.2020.09.001_bib0385","doi-asserted-by":"crossref","DOI":"10.1111\/j.1440-0960.2012.00947.x","article-title":"Isotretinoin: dose, duration and relapse. What does 30 years of usage tell us?","volume":"54","author":"Rademaker","year":"2013","journal-title":"Australas J Dermatol"},{"key":"10.1016\/j.abd.2020.09.001_bib0390","first-page":"17","article-title":"Face to face with oral isotretinoin: a closer look at the spectrum of therapeutic outcomes and why some patients need repeated courses","volume":"5","author":"Del Rosso","year":"2012","journal-title":"J Clin Aesth Dermatol"},{"key":"10.1016\/j.abd.2020.09.001_bib0395","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S0140-6736(11)60321-8","article-title":"Acne vulgaris","volume":"379","author":"Williams","year":"2012","journal-title":"Lancet"},{"issue":"Suppl","key":"10.1016\/j.abd.2020.09.001_bib0400","first-page":"S3","article-title":"The use of isotretinoin in the treatment of acne vulgaris: clinical considerations and future directions","volume":"7","author":"Leyden","year":"2014","journal-title":"J Clin Aesth Dermatol"},{"key":"10.1016\/j.abd.2020.09.001_bib0405","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1111\/j.1468-3083.2010.03933.x","article-title":"Low-cumulative dose isotretinoin treatment in mild-to-moderate acne: efficacy in achieving stable remission","volume":"25","author":"Borghi","year":"2011","journal-title":"J EurAcad Dermatol Venereol"},{"key":"10.1016\/j.abd.2020.09.001_bib0410","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.det.2015.11.002","article-title":"Oral Isotretinoin: new developments relevant to clinical practice","volume":"34","author":"Tan","year":"2016","journal-title":"Dermatol Clin"},{"key":"10.1016\/j.abd.2020.09.001_bib0415","unstructured":"Roche. Roacutan (isotretino\u00edna) Produtos Roche Qu\u00edmicos e Farmac\u00eauticos S.A. Available from: http:\/\/www.anvisa.gov.br\/datavisa\/fila_bula\/frmVisualizarBula.asp?pNuTransacao=14365632016&pIdAnexo=3212245 [accessed 20.10.19]."},{"key":"10.1016\/j.abd.2020.09.001_bib0420","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1177\/1203475415595776","article-title":"Evaluation of evidence for acne remission with oral isotretinoin cumulative dosing of 120\u2013150mg\/kg","volume":"20","author":"Tan","year":"2016","journal-title":"J Cutan Med Surg"},{"key":"10.1016\/j.abd.2020.09.001_bib0425","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1111\/ijd.12942","article-title":"Making sense of the effects of the cumulative dose of isotretinoin in acne vulgaris","volume":"55","author":"Rademaker","year":"2016","journal-title":"Int J Dermatol"},{"issue":"Pt 3","key":"10.1016\/j.abd.2020.09.001_bib0430","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.1016\/S0190-9622(98)70438-4","article-title":"Pharmacokinetics of oral isotretinoin","volume":"39","author":"Wiegand","year":"1998","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.abd.2020.09.001_bib0435","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1001\/archderm.136.10.1231","article-title":"Isotretinoin use and risk of depression, psychotic symptoms, suicide, and attempted suicide","volume":"136","author":"Jick","year":"2000","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.abd.2020.09.001_bib0440","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1016\/j.jaad.2016.12.028","article-title":"Isotretinoin treatment for acne and risk of depression: a systematic review and meta-analysis","volume":"76","author":"Huang","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.abd.2020.09.001_bib0445","doi-asserted-by":"crossref","first-page":"2774","DOI":"10.1038\/ajg.2009.417","article-title":"Isotretinoin is not associated with inflammatory bowel disease: a population-based case\u2013control study","volume":"104","author":"Bernstein","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.abd.2020.09.001_bib0450","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1038\/ajg.2010.124","article-title":"Isotretinoin use and the risk of inflammatory bowel disease: a case\u2013control study","volume":"105","author":"Crockett","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.abd.2020.09.001_bib0455","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1001\/jamadermatol.2013.1344","article-title":"Isotretinoin and risk for inflammatory bowel disease: a nested case-control study and meta-analysis of published and unpublished data","volume":"149","author":"Etminan","year":"2013","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.abd.2020.09.001_bib0460","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1038\/jid.2012.387","article-title":"Isotretinoin use and the risk of inflammatory bowel disease: a population-based cohort study","volume":"133","author":"Alhusayen","year":"2013","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.abd.2020.09.001_bib0465","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/ajg.2014.8","article-title":"Isotretinoin and risk of inflammatory bowel disease: a French nationwide study","volume":"109","author":"Racine","year":"2014","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.abd.2020.09.001_bib0470","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1001\/jamadermatol.2014.1540","article-title":"Isotretinoin exposure and risk of inflammatory bowel disease","volume":"150","author":"Rashtak","year":"2014","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.abd.2020.09.001_bib0475","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1097\/MEG.0000000000000496","article-title":"Does exposure to isotretinoin increase the risk for the development of inflammatory bowel disease? A meta-analysis","volume":"28","author":"Lee","year":"2016","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.abd.2020.09.001_bib0480","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/j.1365-4632.2009.03806.x","article-title":"Comparison of depression, anxiety and life quality in acne vulgaris patients who were treated with either isotretinoin or topical agents","volume":"48","author":"Kaymak","year":"2009","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.abd.2020.09.001_bib0485","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/jid.2010.264","article-title":"Suicidal ideation, mental health problems, and social impairment are increased in adolescents with acne: a population-based study","volume":"131","author":"Halvorsen","year":"2011","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.abd.2020.09.001_bib0490","doi-asserted-by":"crossref","first-page":"136","DOI":"10.5498\/wjp.v6.i1.136","article-title":"Isotretinoin was not associated with depression or anxiety: a twelve-week study","volume":"6","author":"Suarez","year":"2016","journal-title":"World J Psychiatry"},{"key":"10.1016\/j.abd.2020.09.001_bib0495","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.1038\/ajg.2010.303","article-title":"Potential association between the oral tetracycline class of antimicrobials used to treat acne and inflammatory bowel disease","volume":"105","author":"Margolis","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.abd.2020.09.001_bib0500","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1159\/000182270","article-title":"Acute acne flare following isotretinoin administration: potential protective role of low starting dose","volume":"218","author":"Borghi","year":"2009","journal-title":"Dermatology"},{"key":"10.1016\/j.abd.2020.09.001_bib0505","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.jaad.2016.11.028","article-title":"Evidence-based recommendations for the management of acne fulminans and its variants","volume":"77","author":"Greywal","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.abd.2020.09.001_bib0510","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1001\/jamadermatol.2015.3091","article-title":"Laboratory monitoring during isotretinoin therapy for acne: a systematic review and meta-analysis","volume":"152","author":"Lee","year":"2016","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.abd.2020.09.001_bib0515","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.jaad.2019.06.025","article-title":"The clinical utility of laboratory monitoring during isotretinoin therapy for acne and changes to monitoring practices over time","volume":"82","author":"Barbieri","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.abd.2020.09.001_bib0520","first-page":"33","article-title":"Isotretinoin treatment in patients with acne vulgaris: does it impact muscle strength, fatigue, and endurance?","volume":"96","author":"Yildizgoren","year":"2015","journal-title":"Cutis"},{"key":"10.1016\/j.abd.2020.09.001_bib0525","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1111\/j.1365-4632.2008.03491.x","article-title":"Creatine phosphokinase values during isotretinoin treatment for acne","volume":"47","author":"Kaymak","year":"2008","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.abd.2020.09.001_bib0530","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1111\/ijd.13317","article-title":"Observational retrospective study evaluating the effects of oral isotretinoin in keloids and hypertrophic scars","volume":"55","author":"Guadanhim","year":"2016","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.abd.2020.09.001_bib0535","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1001\/jamadermatol.2017.2077","article-title":"Isotretinoin and timing of procedural interventions: a systematic review with consensus recommendations","volume":"153","author":"Spring","year":"2017","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.abd.2020.09.001_bib0540","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1080\/14764172.2018.1444775","article-title":"A 2017 update: Challenging the cosmetic procedural delay following oral isotretinoin therapy","volume":"21","author":"McDonald","year":"2019","journal-title":"J Cosmet Laser Ther"},{"key":"10.1016\/j.abd.2020.09.001_bib0545","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1177\/1203475417701419","article-title":"A systematic review on oral isotretinoin therapy and clinically observable wound healing in acne patients","volume":"21","author":"McDonald","year":"2017","journal-title":"J Cutan Med Surg"},{"key":"10.1016\/j.abd.2020.09.001_bib0550","doi-asserted-by":"crossref","first-page":"186","DOI":"10.4103\/JCAS.JCAS_110_17","article-title":"Standard Guidelines of are: performing procedures in patients on or recently administered with isotretinoin","volume":"10","author":"Mysore","year":"2017","journal-title":"J Cutan Aesthet Surg"},{"key":"10.1016\/j.abd.2020.09.001_bib0555","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1097\/DSS.0000000000001166","article-title":"ASDS Guidelines Task Force: consensus recommendations regarding the safety of lasers, dermabrasion, chemical peels, energy devices, and skin surgery during and after isotretinoin use","volume":"43","author":"Waldman","year":"2017","journal-title":"Dermatol Surg"},{"key":"10.1016\/j.abd.2020.09.001_bib0560","first-page":"575","article-title":"Oral treatment of rosacea with 13-cis-retinoic acid","volume":"32","author":"Nikolowski","year":"1981","journal-title":"Hautarzt"},{"key":"10.1016\/j.abd.2020.09.001_bib0565","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1111\/j.1365-4362.1986.tb04533.x","article-title":"Treatment of rosacea with isotretinoin","volume":"25","author":"Hoting","year":"1986","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.abd.2020.09.001_bib0570","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1001\/archderm.1994.01690030051008","article-title":"A comparison of the efficacy of topical tretinoin and low-dose oral isotretinoin in rosacea","volume":"130","author":"Ertl","year":"1994","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.abd.2020.09.001_bib0575","first-page":"177","article-title":"Severe rosacea treated with oral isotretinoin","volume":"122","author":"Gajardo","year":"1994","journal-title":"Rev Med Chil"},{"key":"10.1016\/j.abd.2020.09.001_bib0580","first-page":"505","article-title":"Systemic isotretinoin in the treatment of rosacea \u2013 doxycycline- and placebo-controlled, randomized clinical study","volume":"8","author":"Gollnick","year":"2010","journal-title":"J Dtsch Dermatol Ges"},{"key":"10.1016\/j.abd.2020.09.001_bib0585","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/j.jid.2016.01.025","article-title":"A randomized-controlled trial of oral low-dose isotretinoin for difficult-to-treat papulopustular rosacea","volume":"136","author":"Sbidian","year":"2016","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.abd.2020.09.001_bib0590","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1111\/j.1365-2230.2004.01472.x","article-title":"Continuous \u201cmicrodose\u201d isotretinoin in adult recalcitrante rosacea","volume":"29","author":"Hofer","year":"2004","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.abd.2020.09.001_bib0595","doi-asserted-by":"crossref","first-page":"73","DOI":"10.2340\/00015555-1204","article-title":"Rosacea treatment with intermediate-dose isotretinoin: follow-up with erythema and sebum measurements","volume":"92","author":"Uslu","year":"2012","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.abd.2020.09.001_bib0600","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s40257-017-0310-0","article-title":"Diagnosis and treatment of rosacea fulminans: a comprehensive review","volume":"19","author":"Walsh","year":"2018","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.abd.2020.09.001_bib0605","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/ajd.12505","article-title":"Phymatous rosacea presenting with leonine facies and clinical response to isotretinoin","volume":"58","author":"Wee","year":"2017","journal-title":"Australas J Dermatol"},{"key":"10.1016\/j.abd.2020.09.001_bib0610","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/bjd.17590","article-title":"Interventions for rosacea based on the phenotype approach: an updated systematic review including GRADE assessments","volume":"181","author":"van Zuuren","year":"2019","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.abd.2020.09.001_bib0615","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1111\/j.1468-3083.2009.03167.x","article-title":"Current topical and systemic approaches to treatment of rosacea","volume":"23","author":"Korting","year":"2009","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.abd.2020.09.001_bib0620","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1111\/bjd.15173","article-title":"Rosacea treatment update: recommendations from the global ROSaceaCOnsensus (ROSCO) panel","volume":"176","author":"Schaller","year":"2017","journal-title":"Br J Dermatol"},{"issue":"Suppl 1","key":"10.1016\/j.abd.2020.09.001_bib0625","doi-asserted-by":"crossref","first-page":"S42","DOI":"10.1016\/j.jaad.2013.04.040","article-title":"Ocular rosacea: a dermatologic perspective","volume":"69","author":"Webster","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.abd.2020.09.001_bib0630","doi-asserted-by":"crossref","first-page":"109","DOI":"10.5935\/0004-2749.20200016","article-title":"Ocular surface changes in the treatment of rosacea: comparison between low-dose oral isotretinoin and doxycycline","volume":"83","author":"Andrade","year":"2020","journal-title":"Arq Bras Oftalmol"},{"key":"10.1016\/j.abd.2020.09.001_bib0635","first-page":"6","article-title":"Informe de Consenso Ibero-Latinoamericano 2016 sobre la clasificaci\u00f3n cl\u00ednica y terap\u00e9utica de la ros\u00e1cea: report of the 2016 Ibero-Latin-American Consensus about clinical and therapeutic classification of rosacea","volume":"44","author":"Grupo Ibero-Latinoamericano de Estudio de la Ros\u00e1cea (GILER) \u2013 CILAD","year":"2016","journal-title":"Med CutanIber Lat Am"},{"key":"10.1016\/j.abd.2020.09.001_bib0640","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1177\/1203475416650427","article-title":"Canadian clinical practice guidelines for rosacea","volume":"20","author":"Asai","year":"2016","journal-title":"J Cutan Med Surg"},{"key":"10.1016\/j.abd.2020.09.001_bib0645","doi-asserted-by":"crossref","first-page":"79","DOI":"10.12788\/j.sder.2016.023","article-title":"Isotretinoin for acne and rosacea","volume":"35","author":"Watson","year":"2016","journal-title":"Semin Cutan Med Surg"},{"key":"10.1016\/j.abd.2020.09.001_bib0650","first-page":"17","article-title":"Update on the management of rosacea from the American Acne & Rosacea Society (AARS)","volume":"12","author":"Del Rosso","year":"2019","journal-title":"J Clin Aesthet Dermatol"},{"issue":"4e","key":"10.1016\/j.abd.2020.09.001_bib0655","doi-asserted-by":"crossref","first-page":"e2","DOI":"10.7241\/ourd.2017.10.2017","article-title":"Systemic isotretinoin treatment and pregnancy: a comparative study of two groups of women: a retrospective analysis of 569 women","volume":"9","author":"Brzezinski","year":"2017","journal-title":"Our Dermatol Online"},{"key":"10.1016\/j.abd.2020.09.001_bib0660","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1111\/j.1365-2133.2010.09894.x","article-title":"The impact of rosacea on quality of life: effects of demographic and clinical characteristics and various treatment modalities","volume":"163","author":"Aksoy","year":"2010","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.abd.2020.09.001_bib0665","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1111\/bjd.15908","article-title":"Prevalence and determinants of seborrhoeic dermatitis in a middle-aged and elderly population: the Rotterdam Study","volume":"178","author":"Sanders","year":"2018","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.abd.2020.09.001_bib0670","first-page":"185","article-title":"Double blind clinical trial in a series of 115 patients with seborrheic dermatitis: prevention of relapses using a topical modulator of Toll like receptor 2","volume":"146","author":"Ionescu","year":"2011","journal-title":"G Ital Dermatol Venereol"},{"key":"10.1016\/j.abd.2020.09.001_bib0675","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1111\/1348-0421.12398","article-title":"Comprehensive pyrosequencing analysis of the bacterial microbiota of the skin of patients with seborrheic dermatitis","volume":"60","author":"Tanaka","year":"2016","journal-title":"Microbiol Immunol"},{"key":"10.1016\/j.abd.2020.09.001_bib0680","doi-asserted-by":"crossref","first-page":"705402","DOI":"10.1155\/2014\/705402","article-title":"Comparison the efficacy of fluconazole and terbinafine in patients with moderate to severe seborrheic dermatitis","volume":"2014","author":"Alizadeh","year":"2014","journal-title":"Dermatol Res Pract"},{"key":"10.1016\/j.abd.2020.09.001_bib0685","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s40257-016-0232-2","article-title":"Topical treatment of facial seborrheic dermatitis: a systematic review","volume":"18","author":"Gupta","year":"2017","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.abd.2020.09.001_bib0690","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1080\/09546634.2018.1473554","article-title":"Treatment of seborrheic dermatitis: a comprehensive review","volume":"30","author":"Borda","year":"2019","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.abd.2020.09.001_bib0695","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1046\/j.1365-2303.2003.00108.x-i1","article-title":"Very low dose isotretinoin is effective in controlling seborrhea","volume":"1","author":"Geissler","year":"2003","journal-title":"J Dtsch Dermatol Ges"},{"key":"10.1016\/j.abd.2020.09.001_bib0700","first-page":"74","article-title":"Tinea versicolor clearance with oral isotretinoin therapy","volume":"5","author":"Bartell","year":"2006","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.abd.2020.09.001_bib0705","article-title":"Improvement of severe facial seborrheic dermatitis following low-dose isotretinoin therapy","author":"Gualtieri","year":"2018","journal-title":"G Ital Dermatol Venereol"},{"key":"10.1016\/j.abd.2020.09.001_bib0710","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1177\/1203475416676806","article-title":"Low-dose isotretinoin for seborrhoeic dermatitis","volume":"21","author":"Rademaker","year":"2017","journal-title":"J Cutan Med Surg"},{"key":"10.1016\/j.abd.2020.09.001_bib0715","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1111\/ijd.13408","article-title":"Low-dose oral isotretinoin for moderate to severe seborrhea and seborrheic dermatitis: a randomized comparative trial","volume":"56","author":"Kamamoto","year":"2017","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.abd.2020.09.001_bib0720","doi-asserted-by":"crossref","first-page":"e1361573","DOI":"10.1080\/19381980.2017.1361573","article-title":"Cutaneous fungal microbiome: Malassezia yeasts in seborrheic dermatitis scalp in a randomized, comparative and therapeutic trial","volume":"9","author":"Kamamoto","year":"2017","journal-title":"Dermatoendocrinol"},{"key":"10.1016\/j.abd.2020.09.001_bib0725","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1111\/j.1365-2133.1997.tb03680.x","article-title":"Isotretinoin-PUVA in women with psoriasis","volume":"136","author":"Anstey","year":"1997","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.abd.2020.09.001_bib0730","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/j.1600-0781.2011.00581.x","article-title":"A single blind randomized clinical study: the efficacy of isotretinoin plus narrow band ultraviolet B in the treatment of psoriasis vulgaris","volume":"27","author":"Mortazavi","year":"2011","journal-title":"Photodermatol Photoimmunol Photomed"},{"key":"10.1016\/j.abd.2020.09.001_bib0735","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1111\/phpp.12125","article-title":"Clinical efficacy of psoralen+sunlight vs. combination of isotretinoin and psoralen+sunlight for the treatment of chronic plaque-type psoriasis vulgaris: a randomized hospital-based study","volume":"30","author":"Gahalaut","year":"2014","journal-title":"Photodermatol Photoimmunol Photomed"},{"key":"10.1016\/j.abd.2020.09.001_bib0740","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1111\/j.1525-1470.2007.00524.x","article-title":"Childhood generalized pustular psoriasis: successful treatment with isotretinoin","volume":"24","author":"Al-Shobaili","year":"2007","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.abd.2020.09.001_bib0745","article-title":"Successful treatment of palmoplantar pustulosis with isotretinoin","volume":"21","author":"Wilken","year":"2015","journal-title":"Dermatol Online J"},{"key":"10.1016\/j.abd.2020.09.001_bib0750","first-page":"CD011628","article-title":"Interventions for chronic palmoplantar pustulosis","volume":"1","author":"Obeid","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.abd.2020.09.001_bib0755","doi-asserted-by":"crossref","first-page":"S76","DOI":"10.1590\/abd1806-4841.2019940211","article-title":"Plaque psoriasis diagnostic and treatment guidelines","volume":"94","author":"Arnone","year":"2019","journal-title":"An Bras Dermatol"},{"key":"10.1016\/j.abd.2020.09.001_bib0760","doi-asserted-by":"crossref","first-page":"e155","DOI":"10.1111\/ced.13953","article-title":"Isotretinoin and hidradenitis suppurativa","volume":"44","author":"J\u00f8rgensen","year":"2019","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.abd.2020.09.001_bib0765","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1177\/1203475418823529","article-title":"Combination therapies for hidradenitis suppurativa: a retrospective chart review of 31 patients","volume":"23","author":"McPhie","year":"2019","journal-title":"J Cutan Med Surg"},{"key":"10.1016\/j.abd.2020.09.001_bib0770","first-page":"1","article-title":"Isotretinoin in the treatment of hidradenitis suppurativa: a retrospective study","author":"Patel","year":"2019","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.abd.2020.09.001_bib0775","first-page":"1036","article-title":"Histologic improvement in photodamage after 12 months of treatment with tretinoin emollient cream (0,02%)","volume":"11","author":"Kircik","year":"2012","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.abd.2020.09.001_bib0780","first-page":"24","article-title":"A randomized, double-blind, split-face study comparing the efficacy and tolerability of three retinol-based products vs. three tretinoin-based products in subjects with moderate to severe facial photodamage","volume":"14","author":"Babcock","year":"2015","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.abd.2020.09.001_bib0785","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/jocd.12131","article-title":"A double-blind randomized study comparing the association of retinol and LR2412 with tretinoin 0.025% in photoaged skin","volume":"14","author":"Bouloc","year":"2015","journal-title":"Cosmet Dermatol"},{"key":"10.1016\/j.abd.2020.09.001_bib0790","doi-asserted-by":"crossref","first-page":"e62643","DOI":"10.1371\/journal.pone.0062643","article-title":"Regulation of retinoid-mediated signaling involved in skin homeostasis by RAR and RXR agonists\/antagonists in mouse skin","volume":"8","author":"Gericke","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.abd.2020.09.001_bib0795","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1046\/j.1524-4725.2000.99210.x","article-title":"Oral isotretinoin as part of the treatment of cutaneous aging","volume":"26","author":"Hernandez-Perez","year":"2000","journal-title":"Dermatol Surg"},{"key":"10.1016\/j.abd.2020.09.001_bib0800","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/j.1540-9740.2007.07145.x","article-title":"Use of oral isotretinoin inphotoaging therapy","volume":"7","author":"Kalil","year":"2008","journal-title":"Skinmed"},{"key":"10.1016\/j.abd.2020.09.001_bib0805","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/j.1468-3083.2008.02947.x","article-title":"Oral isotretinoin in photoaging: clinical and histopathological evidence of efficacy of an off-label indication","volume":"23","author":"Rabello-Fonseca","year":"2009","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.abd.2020.09.001_bib0810","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1111\/j.1365-4632.2009.04310.x","article-title":"A randomized controlled trial about the use of oral isotretinoin for photoaging","volume":"49","author":"Bagatin","year":"2010","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.abd.2020.09.001_bib0815","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1111\/ijd.12191","article-title":"Low-dose oral isotretinoin versus topical retinoic acid for photoaging: a randomized, comparative study","volume":"53","author":"Bagatin","year":"2014","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.abd.2020.09.001_bib0820","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1590\/abd1806-4841.20153703","article-title":"Oral isotretinoin in photoaging: objective histological evidence of efficacy and durability","volume":"90","author":"Bravo","year":"2015","journal-title":"An Bras Dermatol"},{"key":"10.1016\/j.abd.2020.09.001_bib0825","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1002\/1097-0142(195309)6:5<963::AID-CNCR2820060515>3.0.CO;2-Q","article-title":"\u201cField cancerization\u201d in oral stratified squamous epithelium. Clinical implications of multicentric origin","volume":"6","author":"Slaughter","year":"1953","journal-title":"Cancer"},{"key":"10.1016\/j.abd.2020.09.001_bib0830","first-page":"3604","article-title":"p53 mutations in nonmelanoma skin cancer of the head and neck: molecular evidence for field cancerization","volume":"55","author":"Kanjilal","year":"1995","journal-title":"Cancer Res"},{"key":"10.1016\/j.abd.2020.09.001_bib0835","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1159\/000366547","article-title":"Field cancerization: from molecular basis to selective field-directed management of actinic keratosis","volume":"46","author":"Philipp-Dormston","year":"2015","journal-title":"Curr Probl Dermatol"},{"key":"10.1016\/j.abd.2020.09.001_bib0840","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/j.jaad.2005.08.062","article-title":"Chemoprevention of non-melanoma skin cancer","volume":"54","author":"Wright","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.abd.2020.09.001_bib0845","doi-asserted-by":"crossref","first-page":"6542","DOI":"10.1158\/0008-5472.CAN-04-1129","article-title":"Retinoic acid increases the expression of p53 and proapoptotic caspases and sensitizes keratinocytes to apoptosis: a possible explanation for tumor preventive action of retinoids","volume":"64","author":"Mrass","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.abd.2020.09.001_bib0850","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/1476-4598-8-27","article-title":"Identification of the B-Raf\/Mek\/Erk MAP kinase pathway as a target for all-trans retinoic acid during skin cancer promotion","volume":"8","author":"Cheepala","year":"2009","journal-title":"Mol Cancer"},{"key":"10.1016\/j.abd.2020.09.001_bib0855","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1007\/s00105-018-4267-6","article-title":"Low-dose prophylactic oral isotretinoin treatment for 18 years in a patient with epidermodysplasia verruciformis and numerous squamous cell carcinomas","volume":"69","author":"Troyanova-Slavkova","year":"2018","journal-title":"Hautarzt"},{"key":"10.1016\/j.abd.2020.09.001_bib0860","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/j.1365-4632.2006.02948.x","article-title":"Multiple keratoacanthomas in a young woman: report of a case emphasizing medical management and a review of the spectrum of multiple keratoacanthomas","volume":"46","author":"Feldman","year":"2007","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.abd.2020.09.001_bib0865","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1056\/NEJM198009043031005","article-title":"Treatment of keratoacanthomas with oral 13-cis-retinoic acid","volume":"303","author":"Haydey","year":"1980","journal-title":"N Engl J Med"},{"key":"10.1016\/j.abd.2020.09.001_bib0870","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1001\/archderm.1984.01650450097029","article-title":"Oral isotretinoin therapy. Use in a patient with multiple cutaneous squamous cell carcinomas and keratoacanthomas","volume":"120","author":"Levine","year":"1984","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.abd.2020.09.001_bib0875","doi-asserted-by":"crossref","first-page":"499","DOI":"10.7326\/0003-4819-107-4-499","article-title":"Treatment of advanced squamous cell carcinoma of the skin with isotretinoin","volume":"107","author":"Lippman","year":"1987","journal-title":"Ann Intern Med"},{"issue":"Pt 3","key":"10.1016\/j.abd.2020.09.001_bib0880","doi-asserted-by":"crossref","first-page":"S82","DOI":"10.1016\/S0190-9622(98)70451-7","article-title":"Retinoid chemoprevention in the high-risk patient","volume":"39","author":"DiGiovanna","year":"1998","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.abd.2020.09.001_bib0885","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1517\/14656566.9.8.1363","article-title":"Systemic retinoids in chemoprevention of non-melanoma skin cancer","volume":"9","author":"Lens","year":"2008","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.abd.2020.09.001_bib0890","first-page":"753","article-title":"Systemic retinoids for chemoprevention of non-melanoma skin cancer in high-risk patients","volume":"9","author":"Marquez","year":"2010","journal-title":"J Drugs Dermatol"},{"issue":"Pt 2","key":"10.1016\/j.abd.2020.09.001_bib0895","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/S0190-9622(88)70162-0","article-title":"Treatment and prevention of basal cell carcinoma with oral isotretinoin","volume":"19","author":"Peck","year":"1988","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.abd.2020.09.001_bib0900","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1093\/jnci\/84.5.328","article-title":"Long-term therapy with low-dose isotretinoin for prevention of basal cell carcinoma: a multicenter clinical trial. Isotretinoin-Basal Cell Carcinoma Study Group","volume":"84","author":"Tangrea","year":"1992","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.abd.2020.09.001_bib0905","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1016\/S0140-6736(94)90330-1","article-title":"Combination of isotretinoin and calcitriol for precancerous and cancerous skin lesions","volume":"344","author":"Majewski","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/j.abd.2020.09.001_bib0910","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1056\/NEJM198806233182501","article-title":"Prevention of skin cancer in xeroderma pigmentosum with the use of oral isotretinoin","volume":"318","author":"Kraemer","year":"1988","journal-title":"N Engl J Med"},{"key":"10.1016\/j.abd.2020.09.001_bib0915","first-page":"485","article-title":"Prevention of skin cancer in xeroderma pigmentosum with oral isotretinoin","volume":"43","author":"Moshell","year":"1989","journal-title":"Cutis"},{"key":"10.1016\/j.abd.2020.09.001_bib0920","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1111\/jdv.14652","article-title":"Defining the actinic keratosis field: a literature review and discussion","volume":"32","author":"Figueras","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.abd.2020.09.001_bib0925","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1111\/bjd.17103","article-title":"Skin field cancerization \u2013 an in vivo model to prevent nonmelanoma skin cancer: expanding the alternatives for treatment Commentary","volume":"179","author":"Ianhez","year":"2018","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.abd.2020.09.001_bib0930","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1590\/abd1806-4841.20131803","article-title":"Retinoids for prevention and treatment of actinic keratosis","volume":"88","author":"Ianhez","year":"2013","journal-title":"An Bras Dermatol"},{"key":"10.1016\/j.abd.2020.09.001_bib0931","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1093\/jnci\/84.4.235","article-title":"13-cis-retinoic acid and interferon alpha-2a: effective combination therapy for advanced squamous cell carcinoma of the skin","volume":"84","author":"Lippman","year":"1992","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.abd.2020.09.001_bib0935","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/jdv.14092","article-title":"The importance of treating the field in actinic keratosis","volume":"31","author":"Stockfleth","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.abd.2020.09.001_bib0940","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/ijd.14363","article-title":"A randomized, open, controlled trial of tretinoin 0.05% cream vs. low-dose oral isotretinoin for the treatment of field cancerization","volume":"58","author":"Ianhez","year":"2019","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.abd.2020.09.001_bib0932","first-page":"957","article-title":"Trial of retinol and isotretinoin in skin cancer prevention: a randomized, double-blind, controlled trial. Southwest Skin Cancer Prevention Study Group","volume":"6","author":"Levine","year":"1997","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"Suppl 1","key":"10.1016\/j.abd.2020.09.001_bib0945","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1159\/000248870","article-title":"Long-term retinoid therapy is needed for maintenance of cancer chemopreventive effect","volume":"175","author":"Peck","year":"1987","journal-title":"Dermatologica"},{"key":"10.1016\/j.abd.2020.09.001_bib0950","first-page":"562","article-title":"Chemoprevention of nonmelanoma skin cancer with systemic retinoids: practical dosing and management of adverse effects","volume":"32","author":"Otley","year":"2006","journal-title":"Dermatol Surg"},{"key":"10.1016\/j.abd.2020.09.001_bib0955","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1111\/j.1365-2133.2010.09807.x","article-title":"TostiA. Acute hair loss on the limbs in frontal fibrosing alopecia: a clinicopathological study of two cases","volume":"163","author":"Miteva","year":"2010","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.abd.2020.09.001_bib0960","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1159\/000481695","article-title":"Facial papules in frontal fibrosing alopecia: beyond vellus hair follicle involvement","volume":"4","author":"Pirmez","year":"2018","journal-title":"Skin Appendage Disord"},{"key":"10.1016\/j.abd.2020.09.001_bib01245","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1111\/bjd.12683","article-title":"Glabellar red dots in frontal fibrosing alopecia: a further clinical sign of vellus follicle involvement","volume":"170","author":"Pirmez","year":"2014","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.abd.2020.09.001_bib0965","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/j.jaad.2015.02.1129","article-title":"Depression of the frontal veins: a new clinical sign of frontal fibrosing alopecia","volume":"72","author":"Va\u00f1\u00f3-Galv\u00e1n","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.abd.2020.09.001_bib0970","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1111\/bjd.14722","article-title":"Clinical and dermoscopic features of lichen planus pigmentosus in 37 patients with frontal fibrosing alopecia","volume":"175","author":"Pirmez","year":"2016","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.abd.2020.09.001_bib0975","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1159\/000496708","article-title":"Frequency of the types of alopecia at twenty-two specialist hair clinics: a multicenter study","volume":"5","author":"Va\u00f1\u00f3-Galv\u00e1n","year":"2019","journal-title":"Skin Appendage Disord"},{"key":"10.1016\/j.abd.2020.09.001_bib0980","first-page":"988","article-title":"Efficacy of isotretinoin and acitretin in treatment of frontal fibrosing alopecia: retrospective analysis of 54 cases","volume":"16","author":"Rakowska","year":"2017","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.abd.2020.09.001_bib0985","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1080\/09546634.2018.1542480","article-title":"Lichen planopilaris: retrospective study on the characteristics and treatment of 291 patients","volume":"30","author":"Babahosseini","year":"2019","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.abd.2020.09.001_bib0990","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1159\/000464334","article-title":"Successful treatment of facial papules in frontal fibrosing alopecia with oral isotretinoin","volume":"3","author":"Pirmez","year":"2017","journal-title":"Skin Appendage Disord"},{"key":"10.1016\/j.abd.2020.09.001_bib0995","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/j.jaad.2017.04.1118","article-title":"Yellow facial papules associated with frontal fibrosing alopecia: a distinct histologic pattern and response to isotretinoin","volume":"77","author":"Pedrosa","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.abd.2020.09.001_bib01000","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.ad.2017.08.018","article-title":"Facial papules in frontal fibrosing alopecia: good response to isotretinoin","volume":"109","author":"Flores-Terry","year":"2018","journal-title":"Actas Dermosifiliogr"},{"key":"10.1016\/j.abd.2020.09.001_bib01005","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.clindermatol.2014.02.018","article-title":"Red face revisited: disorders of hair growth and the pilosebaceous unit","volume":"32","author":"Ramos-e-Silva","year":"2014","journal-title":"Clin Dermatol"},{"key":"10.1016\/j.abd.2020.09.001_bib01010","doi-asserted-by":"crossref","first-page":"e199","DOI":"10.1111\/jdv.13948","article-title":"Epidemiology, clinical presentation and therapeutic approach in a multicentre series of dissecting cellulitis of the scalp","volume":"31","author":"Segurado-Miravalles","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.abd.2020.09.001_bib01015","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S0140-6736(87)90818-X","article-title":"Dissecting cellulitis of the scalp: response to isotretinoin","volume":"2","author":"Taylor","year":"1987","journal-title":"Lancet"},{"key":"10.1016\/j.abd.2020.09.001_bib01020","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1046\/j.1365-2133.1996.d01-911.x","article-title":"Dissecting cellulitis of the scalp: response to isotretinoin","volume":"134","author":"Scerri","year":"1996","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.abd.2020.09.001_bib01025","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.annder.2014.06.007","article-title":"Dissecting cellulitis of the scalp: a retrospective study of 7 cases confirming the efficacy of oral isotretinoin","volume":"141","author":"Koudoukpo","year":"2014","journal-title":"Ann Dermatol Venereol"},{"key":"10.1016\/j.abd.2020.09.001_bib01030","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1111\/bjd.13999","article-title":"Dissecting cellulitis of the scalp: a retrospective study of 51 patients and review of literature","volume":"174","author":"Badaoui","year":"2016","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.abd.2020.09.001_bib01035","doi-asserted-by":"crossref","first-page":"e83","DOI":"10.1016\/j.jaad.2018.10.078","article-title":"Comment on \u201cFolliculitis decalvans: effectiveness of therapies and prognostic factors in a multicenter series of 60 patients with long-term follow-up\u201d","volume":"80","author":"Litaiem","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.abd.2020.09.001_bib01040","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1111\/jdv.12993","article-title":"Folliculitis decalvans: a multicentre review of 82 patients","volume":"29","author":"Va\u00f1o-Galv\u00e1n","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.abd.2020.09.001_bib01045","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/j.jaad.2018.05.1240","article-title":"Folliculitis decalvans: effectiveness of therapies and prognostic factors in a multicenter series of 60 patients with long-term follow-up","volume":"79","author":"Miguel-G\u00f3mez","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.abd.2020.09.001_bib01050","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1111\/ijd.13874","article-title":"Isotretinoin treatment for folliculitis decalvans: a retrospective case-series study","volume":"57","author":"Aksoy","year":"2018","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.abd.2020.09.001_bib01055","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/j.jaad.2018.07.050","article-title":"Updates in therapeutics for folliculitis decalvans: a systematic review with evidence-based analysis","volume":"80","author":"Rambhia","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.abd.2020.09.001_bib01060","first-page":"1","article-title":"Approach to treatment of refractory dissecting cellulitis of the scalp: a systematic review","author":"Thomas","year":"2019","journal-title":"J Dermatolog Treat"},{"issue":"Pt 2 Suppl","key":"10.1016\/j.abd.2020.09.001_bib01065","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/S0190-9622(82)70061-1","article-title":"Pityriasis rubra pilaris response to 13-cis-retinoic acid (isotretinoin)","volume":"6","author":"Goldsmith","year":"1982","journal-title":"J Am Acad Dermatol"},{"issue":"Pt 1","key":"10.1016\/j.abd.2020.09.001_bib01070","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/S0190-9622(87)70038-3","article-title":"Isotretinoin treatment of pityriasis rubra pilaris","volume":"16","author":"Dicken","year":"1987","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.abd.2020.09.001_bib01075","first-page":"243","article-title":"Systemic therapies of pityriasis rubra pilaris: a systematic review","volume":"17","author":"Kromer","year":"2019","journal-title":"J Dtsch Dermatol Ges"},{"key":"10.1016\/j.abd.2020.09.001_bib01080","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/j.1529-8019.2012.01461.x","article-title":"Treatment of refractory subacute cutaneous lupus erythematosus with oral isotretinoin: a valid therapeutic option","volume":"25","author":"D\u2019Erme","year":"2012","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.abd.2020.09.001_bib01085","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/j.1365-4632.2005.02229.x","article-title":"Temporary remission of disseminated granuloma annulare under oral isotretinoin therapy","volume":"44","author":"Pasmatzi","year":"2005","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.abd.2020.09.001_bib01090","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1136\/sti.2003.006841","article-title":"Oral isotretinoin in the treatment of recalcitrant condylomata acuminata of the cervix: a randomised placebo-controlled trial","volume":"80","author":"Georgala","year":"2004","journal-title":"Sex Transm Infect"},{"key":"10.1016\/j.abd.2020.09.001_bib01095","doi-asserted-by":"crossref","first-page":"569","DOI":"10.4103\/ijdvl.IJDVL_269_18","article-title":"Oral isotretinoin for treating mucocutaneous human papillomavirus infections: a systematic review and meta-analysis","volume":"85","author":"Yang","year":"2019","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"10.1016\/j.abd.2020.09.001_bib01100","doi-asserted-by":"crossref","first-page":"18","DOI":"10.4103\/2229-5178.73252","article-title":"Darier-White disease in siblings responding to isotretinoin","volume":"1","author":"Bhat","year":"2010","journal-title":"Indian Dermatol Online J"},{"key":"10.1016\/j.abd.2020.09.001_bib01105","doi-asserted-by":"crossref","first-page":"e63","DOI":"10.5546\/aap.2011.e63","article-title":"Darier-White disease treated with oral isotretinoin","volume":"109","author":"Eimer","year":"2011","journal-title":"Arch Argent Pediatr"},{"key":"10.1016\/j.abd.2020.09.001_bib01110","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1111\/j.1365-4632.2006.02830.x","article-title":"Isotretinoin \u2013 unapproved indications\/uses and dosage: a physician's reference","volume":"45","author":"Sehgal","year":"2006","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.abd.2020.09.001_bib01115","doi-asserted-by":"crossref","first-page":"593","DOI":"10.4103\/idoj.IDOJ_14_19","article-title":"A new trigger for aquagenic wrinkling: isotretinoin","volume":"10","author":"Akta\u015f","year":"2019","journal-title":"Indian Dermatol Online J"},{"key":"10.1016\/j.abd.2020.09.001_bib01120","first-page":"563","article-title":"Severe aphthous stomatitis secondary to vitamin B12 deficiency with isotretinoin therapy","volume":"5","author":"Vigarios","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.abd.2020.09.001_bib01125","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1111\/pde.13969","article-title":"Recalcitrant granulomatous periorificial dermatites with good response to low-dose oral isotretinoin","volume":"36","author":"Rodriguez-Garijo","year":"2019","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.abd.2020.09.001_bib01130","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1684\/ejd.2019.3569","article-title":"Additional findings supporting systemic isotretinoin as a useful treatment for Galli-Galli disease","volume":"29","author":"Tomasini","year":"2019","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.abd.2020.09.001_bib01135","article-title":"Severe acneiform eruption associated with vemurafenib with response to isotretinoin","volume":"24","author":"Elosua-Gonzalez","year":"2018","journal-title":"Dermatol Online J"},{"key":"10.1016\/j.abd.2020.09.001_bib01140","doi-asserted-by":"crossref","first-page":"579","DOI":"10.4103\/0378-6323.183632","article-title":"Successful treatment of recurrent dermatophytosis with isotretinoin and itraconazole","volume":"82","author":"Ardeshna","year":"2016","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"10.1016\/j.abd.2020.09.001_bib01145","doi-asserted-by":"crossref","first-page":"68","DOI":"10.4103\/0378-6323.194292","article-title":"Isotretinoin may affect pharmacokinetics of itraconazole in the skin: is it rational to combine both for the treatment of dermatophytosis?","volume":"83","author":"Srivastava","year":"2017","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"10.1016\/j.abd.2020.09.001_bib01150","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1111\/ijd.13293","article-title":"Low-dose oral isotretinoin therapy in lichen planus pigmentosus: an open-label non-randomized prospective pilot study","volume":"55","author":"Muthu","year":"2016","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.abd.2020.09.001_bib01155","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/j.jaad.2014.06.013","article-title":"Efficacy of oral retinoids in treatment-resistant lichen planopilaris","volume":"71","author":"Spano","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.abd.2020.09.001_bib01160","doi-asserted-by":"crossref","first-page":"8173182","DOI":"10.1155\/2016\/8173182","article-title":"The role of isotretinoin therapy for Cushing's disease: results of a prospective study","volume":"2016","author":"Vilar","year":"2016","journal-title":"Int J Endocrinol"},{"key":"10.1016\/j.abd.2020.09.001_bib01165","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1590\/abd1806-4841.20153192","article-title":"Sebaceous hyperplasia: systemic treatment with isotretinoin","volume":"90","author":"Tagliolatto","year":"2015","journal-title":"An Bras Dermatol"},{"key":"10.1016\/j.abd.2020.09.001_bib01170","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/j.1365-2133.1993.tb11874.x","article-title":"Fordyce spots responding to isotretinoin therapy","volume":"129","author":"Monk","year":"1993","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.abd.2020.09.001_bib01175","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1111\/j.1365-2133.1984.tb04054.x","article-title":"The treatment of steatocystoma multiplex suppurativum with isotretinoin","volume":"111","author":"Statham","year":"1984","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.abd.2020.09.001_bib01180","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1111\/j.1468-3083.2009.03219.x","article-title":"Confluent and reticulated papillomatosis: favourable response to low-dose isotretinoin","volume":"23","author":"Erkek","year":"2009","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.abd.2020.09.001_bib01185","doi-asserted-by":"crossref","first-page":"300","DOI":"10.2340\/00015555-0416","article-title":"Erosive pustular dermatosis of the scalp: a case treated successfully with isotretinoin","volume":"88","author":"Petersen","year":"2008","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.abd.2020.09.001_bib01190","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.jaad.2015.09.046","article-title":"The use of oral antibiotics before isotretinoin therapy in patients with acne","volume":"74","author":"Nagler","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.abd.2020.09.001_bib01195","doi-asserted-by":"crossref","first-page":"15029","DOI":"10.1038\/nrdp.2015.29","article-title":"Acne vulgaris","volume":"1","author":"Tuchayi","year":"2015","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.abd.2020.09.001_bib01200","doi-asserted-by":"crossref","first-page":"e13251","DOI":"10.1111\/dth.13251","article-title":"Low dose of isotretinoin: a comprehensive review","volume":"33","author":"Abdelmaksoud","year":"2020","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.abd.2020.09.001_bib01205","first-page":"e12873","article-title":"Perceptions about oral isotretinoin treatment","volume":"32","author":"Tugrul","year":"2019","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.abd.2020.09.001_bib01210","unstructured":"CEBM. The Oxford Centre for Evidence Based Medicine 2009 Levels of Evidence guidelines were originally used. [cited 17.04.20] Available from: https:\/\/www.cebm.net\/2009\/06\/oxfordcentre-evidence-based-medicine-levelsevidence-march-2009."}],"container-title":["Anais Brasileiros de Dermatologia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0365059620302336?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0365059620302336?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T23:39:09Z","timestamp":1759793949000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0365059620302336"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":245,"alternative-id":["S0365059620302336"],"URL":"https:\/\/doi.org\/10.1016\/j.abd.2020.09.001","relation":{},"ISSN":["0365-0596"],"issn-type":[{"value":"0365-0596","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Consensus on the use of oral isotretinoin in dermatology - Brazilian Society of Dermatology","name":"articletitle","label":"Article Title"},{"value":"Anais Brasileiros de Dermatologia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.abd.2020.09.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Sociedade Brasileira de Dermatologia. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}